Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Heidelberg University Researchers Classify Brain and Spine Metastases

Published: Monday, February 07, 2011
Last Updated: Monday, February 07, 2011
Bookmark and Share
Researchers at the Department of Neuropathology at Heidelberg University in Germany have shown that Rosetta Genomics' miRview™ mets is a powerful tool to guide diagnosis of metastatic brain and spine cancer cases. The study, titled "Accurate Classification of Metastatic Brain Tumors Using a Novel MicroRNA-Based Test," was published online, January 31, and is set to be published in the February 11, 2011 print edition of The Oncologist.

The abstract of the study may be viewed online at The Oncologist website: http://theoncologist.alphamedpress.org/cgi/content/abstract/theoncologist.2010-0305v1

The study consisted of a proof-of-concept phase and a validation phase. In the proof-of-concept phase, brain and spine metastases from known primary tumors were analyzed with the miRview™ mets assay. In the validation phase, a cohort of brain and spine metastatic samples of true Cancer of Unknown Primary patients were studied, and concordance between results generated by miRview™ mets and the clinical and pathological evaluation was examined.
Results from the validation phase demonstrated that primary origin prediction from miRview™ mets was in agreement with the clinical or pathological evaluation in 80% of the cases.
Underscoring the value of miRview™ mets, the study describes a case of a breast cancer patient with brain metastasis. When analyzed with miRview™ mets, the origin of the metastasis was surprisingly diagnosed as melanoma. Additional pathology testing supported this diagnosis. Based on these findings, the primary breast cancer was also tested with the miRview™ mets assay as well as additional pathology testing, and was found to be melanoma misdiagnosed as breast cancer.

"Metastatic cancer can present a significant diagnostic challenge to pathologists searching for the primary origin," noted Dr. Wolf C. Mueller from the Department of Neuropathology at Heidelberg University, who led the study. "The diagnostic process can be time-consuming, and can lead to limited results. Our study demonstrated that miRview™ mets is a powerful tool for diagnosing cancer of uncertain or unknown primary, and may also offer new diagnostic avenues to explore."

"This study, along with the recently completed study by researchers from M. D. Anderson, are two post-marketing validation studies conducted by leading cancer centers that demonstrate the ability of miRview™ mets to accurately identify the origin of metastases in cancer cases with unknown or uncertain primaries. We are pleased with the consistently strong performance of our microRNA-based assay in diagnosing cancer of true uncertain or unknown primary," noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. "Our unique microRNA-based technologies have enabled us to recently launch miRview™ mets², and we firmly believe that with its expanded tumor panel and enhanced classifiers, it will further improve physicians' ability to accurately diagnose cancer of unknown or uncertain primary origin in order to optimize treatment options for patients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Allogeneic Stem Cell Transplant Shows Promise for Treatment-Resistant CLL
University of Heidelberg researchers publish study results in the journal Blood.
Wednesday, July 07, 2010
Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!